These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 29703539

  • 41. Melanoregulin-Anaplastic Lymphoma Kinase (ALK), a Novel ALK Rearrangement That Responds to Crizotinib in Lung Adenocarcinoma.
    Wang L, Yao S, Teng L, Zhang W, Chen L.
    J Thorac Oncol; 2020 Mar; 15(3):e44-e46. PubMed ID: 32093861
    [No Abstract] [Full Text] [Related]

  • 42. Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.
    Mattar MS, Chang J, Benayed R, Halpenny D, Powers A, Kleiner DE, Drilon A, Kris MG.
    Clin Lung Cancer; 2020 Jan; 21(1):e25-e29. PubMed ID: 31690489
    [No Abstract] [Full Text] [Related]

  • 43. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.
    Takegawa N, Hayashi H, Iizuka N, Takahama T, Ueda H, Tanaka K, Takeda M, Nakagawa K.
    Ann Oncol; 2016 May; 27(5):953-5. PubMed ID: 26811347
    [No Abstract] [Full Text] [Related]

  • 44. Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report.
    Wang H, Zhu S, Li Z, Qi X, Zhang L, Ke L, Lin Y.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30316. PubMed ID: 36107507
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.
    Li M, Tang Q, Chen S, Wang Y.
    Lung Cancer; 2021 Jan 02; 151():98-100. PubMed ID: 33280926
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib.
    Zhao G, Chen L, Xiao M, Yang S.
    Lung Cancer; 2021 Feb 02; 152():189-192. PubMed ID: 33419583
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.
    Zhang J, Huang J, Li Q, Lin H, Luo Z, Chen R.
    Lung Cancer; 2021 Sep 02; 159():171-174. PubMed ID: 34266695
    [No Abstract] [Full Text] [Related]

  • 55. ALK-positive adenocarcinoma of the lung expressing neuroendocrine markers and presenting as a "pituitary adenoma".
    Mengoli MC, Bertolini F, Maur M, Barbieri F, Longo L, Gasparri P, Tiseo M, Rossi G.
    Pathologica; 2017 Dec 02; 109(4):408-411. PubMed ID: 29449735
    [Abstract] [Full Text] [Related]

  • 56. EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.
    Matsuda H, Hara M, Iwakami SI, Takahashi K.
    BMJ Case Rep; 2021 Apr 27; 14(4):. PubMed ID: 33906872
    [Abstract] [Full Text] [Related]

  • 57. Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.
    Yokoyama A, Tamura A, Miyakawa K, Kusaka K, Shimada M, Hirose T, Matsui H, Kitani M, Hebisawa A, Ohta K.
    Intern Med; 2018 Aug 15; 57(16):2377-2382. PubMed ID: 29526950
    [Abstract] [Full Text] [Related]

  • 58. Anaplastic Lymphoma Kinase (ALK) Positive Neuroendocrine Tumor of Lung With Favorable Response to Alectinib (ALK Inhibitor).
    Ghimire B, Pokharel A, Karki U, Thapa S, Chisti MM.
    Clin Lung Cancer; 2023 May 15; 24(3):e113-e116. PubMed ID: 36690569
    [No Abstract] [Full Text] [Related]

  • 59. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
    Hui B, Zhang J, Shi X, Xing F, Shao YW, Wang Y, Zhang X, Wang S.
    Jpn J Clin Oncol; 2020 Dec 16; 50(12):1470-1474. PubMed ID: 32845005
    [Abstract] [Full Text] [Related]

  • 60. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
    Gadgeel S, Shaw AT, Barlesi F, Crinò L, Yang JC, Dingemans AC, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Kotb A, Ou SI.
    Br J Cancer; 2018 Jan 16; 118(1):38-42. PubMed ID: 29149104
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.